Cargando…
Immune Checkpoint Inhibitor Dosing: Can We Go Lower Without Compromising Clinical Efficacy?
In just a few years, immune checkpoint inhibitors have dramatically changed the landscape in oncology, offering durable responses and improved survival for many patients across several tumor types. With more than 3,300 new agents in the immuno-oncology pipeline plus a wide array of combinations bein...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society of Clinical Oncology
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690659/ https://www.ncbi.nlm.nih.gov/pubmed/31348737 http://dx.doi.org/10.1200/JGO.19.00142 |